Exact Sciences Stock Performance
| EXAS Stock | USD 101.73 0.00 0.00% |
On a scale of 0 to 100, EXACT Sciences holds a performance score of 20. The firm owns a Beta (Systematic Risk) of -0.18, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning EXACT Sciences are expected to decrease at a much lower rate. During the bear market, EXACT Sciences is likely to outperform the market. Please check EXACT Sciences' maximum drawdown, and the relationship between the standard deviation and expected short fall , to make a quick decision on whether EXACT Sciences' current price history will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in EXACT Sciences are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent basic indicators, EXACT Sciences unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.18 | Five Day Return (0.07) | Ten Year Return 1.1 K | All Time Return 578.27 |
1 | Exact Sciences is an Intriguing Medical Stock to Watch After Q3 Earnings | 11/05/2025 |
2 | Police Firemen s Retirement System of New Jersey Acquires 5,632 Shares of Exact Sciences Corporation EXAS | 11/17/2025 |
3 | 100 Invested In Exact Sciences 15 Years Ago Would Be Worth This Much Today | 12/01/2025 |
4 | Capital Fund Management S.A. Invests 4.41 Million in Exact Sciences Corporation EXAS | 12/02/2025 |
5 | Has Exact Sciences Rally of Over 50 percent Left Room for Further Upside | 12/04/2025 |
6 | Acquisition by Brian Baranick of 4725 shares of EXACT Sciences subject to Rule 16b-3 | 12/05/2025 |
7 | Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect MRD Test in Early Triple-Negative Breast Cancer at SABCS | 12/11/2025 |
8 | Is Exact Sciences Stock Still Attractive After a 78.1 percent Surge in 2025 - simplywall.st | 12/18/2025 |
9 | Disposition of 38715 shares by Aaron Bloomer of EXACT Sciences subject to Rule 16b-3 | 12/23/2025 |
10 | Disposition of 14938 shares by Brian Baranick of EXACT Sciences at 101.59 subject to Rule 16b-3 | 12/24/2025 |
11 | Acquisition by Kevin Conroy of 244931 shares of EXACT Sciences subject to Rule 16b-3 | 12/30/2025 |
| Begin Period Cash Flow | 609.7 M | |
| Total Cashflows From Investing Activities | -442.2 M |
EXACT Sciences Relative Risk vs. Return Landscape
If you would invest 5,775 in EXACT Sciences on October 7, 2025 and sell it today you would earn a total of 4,398 from holding EXACT Sciences or generate 76.15% return on investment over 90 days. EXACT Sciences is currently generating 0.966% in daily expected returns and assumes 3.7989% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than EXACT, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
EXACT Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for EXACT Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as EXACT Sciences, and traders can use it to determine the average amount a EXACT Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2543
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EXAS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average EXACT Sciences is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of EXACT Sciences by adding it to a well-diversified portfolio.
EXACT Sciences Fundamentals Growth
EXACT Stock prices reflect investors' perceptions of the future prospects and financial health of EXACT Sciences, and EXACT Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on EXACT Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0109 | ||||
| Profit Margin | (0.32) % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 20.83 B | ||||
| Shares Outstanding | 189.77 M | ||||
| Price To Earning | (38.17) X | ||||
| Price To Book | 7.72 X | ||||
| Price To Sales | 6.26 X | ||||
| Revenue | 2.76 B | ||||
| Gross Profit | 2.14 B | ||||
| EBITDA | (789.33 M) | ||||
| Net Income | (1.03 B) | ||||
| Cash And Equivalents | 728.04 M | ||||
| Cash Per Share | 4.11 X | ||||
| Total Debt | 2.75 B | ||||
| Debt To Equity | 0.77 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 13.20 X | ||||
| Cash Flow From Operations | 210.54 M | ||||
| Earnings Per Share | (5.35) X | ||||
| Market Capitalization | 19.31 B | ||||
| Total Asset | 5.93 B | ||||
| Retained Earnings | (4.5 B) | ||||
| Working Capital | 839.24 M | ||||
| Current Asset | 325.86 M | ||||
| Current Liabilities | 26.72 M | ||||
About EXACT Sciences Performance
Assessing EXACT Sciences' fundamental ratios provides investors with valuable insights into EXACT Sciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the EXACT Sciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 81.12 | 121.62 | |
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.17) | (0.16) | |
| Return On Equity | (0.39) | (0.40) |
Things to note about EXACT Sciences performance evaluation
Checking the ongoing alerts about EXACT Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for EXACT Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| EXACT Sciences appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 2.76 B. Net Loss for the year was (1.03 B) with profit before overhead, payroll, taxes, and interest of 2.14 B. | |
| EXACT Sciences has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Acquisition by Kevin Conroy of 244931 shares of EXACT Sciences subject to Rule 16b-3 |
- Analyzing EXACT Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether EXACT Sciences' stock is overvalued or undervalued compared to its peers.
- Examining EXACT Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating EXACT Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of EXACT Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of EXACT Sciences' stock. These opinions can provide insight into EXACT Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.